DUBLIN, Oct. 13, 2016 /PRNewswire/ -- Allergan plc
(NYSE: AGN) announced today a collaboration with
SonarMD®, a leader in population health management, on
the development of clinical decision support (CDS) and patient
engagement tools which can be used to facilitate physician
identification of patients suffering from Irritable Bowel Syndrome
with Diarrhea (IBS-D) in clinical practice and monitor their
treatment outcomes. Moreover, the companies will establish a
patient engagement platform which can be used to evaluate symptoms
and health outcomes among patients with IBS-D in a real-world
clinical setting.
Logo -
http://photos.prnewswire.com/prnh/20150612/222796LOGO
This platform allows healthcare practitioners to securely
engage, monitor, and manage IBS-D patients between visits via
ongoing health assessments evaluating patient symptoms, quality of
life, and treatment impacts. Data from these assessments can alert
physicians to any change in a patient's condition that may require
intervention, which could lead to improved health outcomes for
patients and decreased costs of care. This platform will also
provide an opportunity to generate real-world data on the impact of
current treatment options for patients with IBS-D.
SonarMD is the developer of a cloud-based care management
platform – created by noted gastroenterologist Lawrence Kosinski, MD, MBA and Managing Partner,
Illinois Gastroenterology Group – that supports improved patient
access, care coordination and healthcare management for patients
with chronic illnesses. The SonarMD platform delivers care
management algorithms to help providers and patients dramatically
improve the management of chronic diseases in the new era of
value-based care. SonarMD has previously applied this technology to
support patients with Crohn's Disease, combining the use of
clinical metrics derived from CDS tools with patient reported
outcomes.
Allergan and SonarMD will leverage the Sonar platform for use
with IBS-D patients with the goal of optimizing efficient diagnosis
and effective use of treatment options to manage IBS-D in clinical
practice. This represents the first application of the SonarMD
platform for IBS.
"The collaboration with SonarMD is a further demonstration of
Allergan's long-term commitment to improving the lives of patients
with IBS-D through better patient care and access to innovative
treatments," said Gavin Corcoran,
M.D., chief medical officer, Allergan. "The sooner patients can be
effectively identified and diagnosed, the sooner they can receive
the treatments they need to alleviate the burdensome symptoms of
IBS-D."
"Traditionally, the limited diagnostic and therapeutic options
available for patients suffering from irritable bowel syndrome,
combined with the reluctance of those patients to discuss their
symptoms with healthcare practitioners, has presented a major
barrier to providing them with the most effective care. The
collaboration between SonarMD and Allergan is focused on developing
tools which will help providers more efficiently identify IBS-D
patients, deliver quality care and, simultaneously, foster
meaningful patient engagement," said Jonathan Rosenberg, SonarMD's Medical Director.
"I am excited about the potential for this project to generate
meaningful patient reported data which will lead to better care
outcomes for all IBS-D sufferers through more effective care
delivery from their providers."
About IBS-D
Irritable bowel syndrome with diarrhea (IBS-D) is a functional
bowel disorder characterized by chronic abdominal pain and frequent
diarrhea, which affects approximately 15 million patients in the
U.S. Although the exact cause of IBS-D is not known, symptoms
are thought to result from a disturbance in the way the
gastrointestinal tract and nervous system interact.
IBS-D can be debilitating and there are limited therapeutic
options for managing the chronic symptoms. IBS-D is associated with
economic burden in direct medical costs and indirect social costs
such as absenteeism and lost productivity, along with decreased
quality of life.
About SonarMD®
SonarMD, a Rolling Meadows,
Illinois based Delaware LLC, is committed to the development
of Care Management Algorithms for the management of patients with
chronic disease. Its leadership team combines some of the nation's
top leaders in clinical medicine with the technology strength of
Mutare, Inc. Together they intend to bring the leadership and tools
for providers to succeed in Population Health and deliver better
patient outcomes. For more information, visit sonarmd.com or call
847-370-8878.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin,
Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and
best-in-class products for the central nervous system, eye care,
medical aesthetics and dermatology, gastroenterology, women's
health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Company's R&D model, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. This approach has led to Allergan building
one of the broadest development pipelines in the pharmaceutical
industry with 65+ mid-to-late stage pipeline programs in
development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100
countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends
and information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements. Actual
results may differ materially from Allergan's current
expectations depending upon a number of factors
affecting Allergan's business. These factors include,
among others, the risks associated with acquisition transactions;
the difficulty of predicting the timing or outcome of FDA
approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand
for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not
limited to Allergan's Quarterly Report on Form 10-Q for
the quarter ended December 31, 2015 (such periodic public
filings having been filed under the "Actavis plc" name) and from
time to time in Allergan's other investor communications.
Except as expressly required by law, Allergan disclaims
any intent or obligation to update these forward-looking
statements.
CONTACTS:
Investors:
Lisa
DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
Fran DeSena
(973) 517-3132
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-partners-with-sonarmd-to-develop-innovative-ibs-d-patient-engagement-platform-for-better-identification-and-care-of-ibs-d-patients-300344147.html
SOURCE Allergan plc